Monthly risedronate (Actonel) for postmenopausal osteoporosis.
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D005252:Fees, Pharmaceutical; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control*; D017698:Postmenopause; D000068296:Risedronic Acid; D016896:Treatment Outcome; D014481:United States
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid